Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized, double-blind, placebo-controlled study of AKCEA-APOCIII-LRX in familial chylomicronemia syndrome
2020-002536-67Phase 3Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Sep 2020
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary chylomicronemia (FCS) and familial hypertriglyceridemia (FHTG) comparing AKCEA-APOCIII-LRX with Placebo (2 arms). Primary endpoint: Percent change in fasting triglycerides from baseline at 6 months. Started Sep 2020; status: completed.
02
Drugs
olezarsen
03
Conditions
primary chylomicronemia (FCS)familial hypertriglyceridemia (FHTG)
Beyond the preview
Go deeper on 2020-002536-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002536-67.